Abstract
Bacillus Calmette-Guerin (BCG), a live attenuated form of Mycobacterium bovis ( M. bovis ), is the most effective intravesical agent in the treatment of non-invasive bladder cancer. This therapy can cause minor complications like urinary frequency, fever, dysuria and hematuria, but it can also cause more serious systemic complications such as hepatitis, pneumonitis and sepsis. Miliary tuberculosis is a very rare complication of BCG immunotherapy and is associated to high mortality, thus this diagnosis must be early considered and early treatment should be implemented. The authors report a case of miliary tuberculosis after treatment with intravesical BCG, with isolation of M. bovis . The patient presented clinical and imaging improvement after initiation of tuberculostatic agents. J Med Cases. 2017;8(7):233-235 doi: https://doi.org/10.14740/jmc2862w
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
